nodes	percent_of_prediction	percent_of_DWPC	metapath
Guanabenz—CYP1A2—Flutamide—prostate cancer	0.0998	0.347	CbGbCtD
Guanabenz—CYP1A2—Estrone—prostate cancer	0.0721	0.251	CbGbCtD
Guanabenz—CYP1A2—Conjugated Estrogens—prostate cancer	0.0472	0.164	CbGbCtD
Guanabenz—CYP1A2—Estradiol—prostate cancer	0.0414	0.144	CbGbCtD
Guanabenz—CYP1A2—Etoposide—prostate cancer	0.027	0.0941	CbGbCtD
Guanabenz—NISCH—Paclitaxel—Cabazitaxel—prostate cancer	0.00638	0.595	CbGdCrCtD
Guanabenz—CYP1A2—urine—prostate cancer	0.00558	0.151	CbGeAlD
Guanabenz—NISCH—prostate gland—prostate cancer	0.00506	0.137	CbGeAlD
Guanabenz—NISCH—urethra—prostate cancer	0.00339	0.0915	CbGeAlD
Guanabenz—Guanfacine—CYP2C19—prostate cancer	0.00303	0.611	CrCbGaD
Guanabenz—NISCH—Paclitaxel—Docetaxel—prostate cancer	0.00265	0.247	CbGdCrCtD
Guanabenz—NISCH—bone marrow—prostate cancer	0.00261	0.0704	CbGeAlD
Guanabenz—ADRA2C—prostate gland—prostate cancer	0.00231	0.0624	CbGeAlD
Guanabenz—NISCH—testis—prostate cancer	0.00223	0.0602	CbGeAlD
Guanabenz—ADRA2C—seminal vesicle—prostate cancer	0.00195	0.0528	CbGeAlD
Guanabenz—Guanfacine—CYP3A4—prostate cancer	0.00192	0.389	CrCbGaD
Guanabenz—ADRA2A—prostate gland—prostate cancer	0.00184	0.0498	CbGeAlD
Guanabenz—NISCH—Podofilox—Etoposide—prostate cancer	0.0017	0.159	CbGdCrCtD
Guanabenz—NISCH—lymph node—prostate cancer	0.00161	0.0436	CbGeAlD
Guanabenz—ADRA2C—renal system—prostate cancer	0.00157	0.0425	CbGeAlD
Guanabenz—ADRA2A—seminal vesicle—prostate cancer	0.00156	0.0421	CbGeAlD
Guanabenz—ADRA2C—urethra—prostate cancer	0.00155	0.0418	CbGeAlD
Guanabenz—CYP1A2—renal system—prostate cancer	0.00137	0.0369	CbGeAlD
Guanabenz—ADRA2A—urethra—prostate cancer	0.00123	0.0333	CbGeAlD
Guanabenz—ADRA2C—testis—prostate cancer	0.00102	0.0275	CbGeAlD
Guanabenz—ADRA2A—testis—prostate cancer	0.000812	0.0219	CbGeAlD
Guanabenz—ADRA2C—lymph node—prostate cancer	0.000738	0.0199	CbGeAlD
Guanabenz—ADRA2A—lymph node—prostate cancer	0.000589	0.0159	CbGeAlD
Guanabenz—Skin disorder—Docetaxel—prostate cancer	0.000136	0.000273	CcSEcCtD
Guanabenz—Agitation—Prednisone—prostate cancer	0.000136	0.000273	CcSEcCtD
Guanabenz—Oedema—Capecitabine—prostate cancer	0.000136	0.000272	CcSEcCtD
Guanabenz—Angioedema—Prednisone—prostate cancer	0.000135	0.000271	CcSEcCtD
Guanabenz—Infection—Capecitabine—prostate cancer	0.000135	0.00027	CcSEcCtD
Guanabenz—Urticaria—Etoposide—prostate cancer	0.000134	0.000268	CcSEcCtD
Guanabenz—Haemoglobin—Epirubicin—prostate cancer	0.000134	0.000268	CcSEcCtD
Guanabenz—Anorexia—Docetaxel—prostate cancer	0.000134	0.000268	CcSEcCtD
Guanabenz—Malaise—Prednisone—prostate cancer	0.000134	0.000268	CcSEcCtD
Guanabenz—Shock—Capecitabine—prostate cancer	0.000133	0.000267	CcSEcCtD
Guanabenz—Body temperature increased—Etoposide—prostate cancer	0.000133	0.000267	CcSEcCtD
Guanabenz—Abdominal pain—Etoposide—prostate cancer	0.000133	0.000267	CcSEcCtD
Guanabenz—Nervous system disorder—Capecitabine—prostate cancer	0.000133	0.000267	CcSEcCtD
Guanabenz—Haemorrhage—Epirubicin—prostate cancer	0.000133	0.000267	CcSEcCtD
Guanabenz—Thrombocytopenia—Capecitabine—prostate cancer	0.000133	0.000266	CcSEcCtD
Guanabenz—Syncope—Prednisone—prostate cancer	0.000133	0.000266	CcSEcCtD
Guanabenz—Tachycardia—Capecitabine—prostate cancer	0.000132	0.000265	CcSEcCtD
Guanabenz—Skin disorder—Capecitabine—prostate cancer	0.000132	0.000264	CcSEcCtD
Guanabenz—Oedema peripheral—Epirubicin—prostate cancer	0.000131	0.000263	CcSEcCtD
Guanabenz—Hypotension—Docetaxel—prostate cancer	0.000131	0.000262	CcSEcCtD
Guanabenz—Connective tissue disorder—Epirubicin—prostate cancer	0.000131	0.000262	CcSEcCtD
Guanabenz—Loss of consciousness—Prednisone—prostate cancer	0.00013	0.000261	CcSEcCtD
Guanabenz—Anorexia—Capecitabine—prostate cancer	0.000129	0.000259	CcSEcCtD
Guanabenz—Nausea—Estradiol—prostate cancer	0.000129	0.000259	CcSEcCtD
Guanabenz—Vomiting—Mitoxantrone—prostate cancer	0.000129	0.000258	CcSEcCtD
Guanabenz—Hypertension—Prednisone—prostate cancer	0.000128	0.000256	CcSEcCtD
Guanabenz—Rash—Mitoxantrone—prostate cancer	0.000128	0.000256	CcSEcCtD
Guanabenz—Dermatitis—Mitoxantrone—prostate cancer	0.000128	0.000256	CcSEcCtD
Guanabenz—Musculoskeletal discomfort—Docetaxel—prostate cancer	0.000128	0.000256	CcSEcCtD
Guanabenz—Headache—Mitoxantrone—prostate cancer	0.000127	0.000254	CcSEcCtD
Guanabenz—Hypotension—Capecitabine—prostate cancer	0.000127	0.000254	CcSEcCtD
Guanabenz—Arthralgia—Prednisone—prostate cancer	0.000126	0.000253	CcSEcCtD
Guanabenz—Myalgia—Prednisone—prostate cancer	0.000126	0.000253	CcSEcCtD
Guanabenz—Paraesthesia—Docetaxel—prostate cancer	0.000126	0.000252	CcSEcCtD
Guanabenz—Erythema multiforme—Epirubicin—prostate cancer	0.000126	0.000252	CcSEcCtD
Guanabenz—Anxiety—Prednisone—prostate cancer	0.000126	0.000252	CcSEcCtD
Guanabenz—Dyspnoea—Docetaxel—prostate cancer	0.000125	0.00025	CcSEcCtD
Guanabenz—Discomfort—Prednisone—prostate cancer	0.000125	0.00025	CcSEcCtD
Guanabenz—Eye disorder—Epirubicin—prostate cancer	0.000124	0.000249	CcSEcCtD
Guanabenz—Hypersensitivity—Etoposide—prostate cancer	0.000124	0.000249	CcSEcCtD
Guanabenz—Tinnitus—Epirubicin—prostate cancer	0.000124	0.000248	CcSEcCtD
Guanabenz—Haemoglobin—Doxorubicin—prostate cancer	0.000124	0.000248	CcSEcCtD
Guanabenz—Musculoskeletal discomfort—Capecitabine—prostate cancer	0.000124	0.000248	CcSEcCtD
Guanabenz—Dyspepsia—Docetaxel—prostate cancer	0.000123	0.000247	CcSEcCtD
Guanabenz—Haemorrhage—Doxorubicin—prostate cancer	0.000123	0.000247	CcSEcCtD
Guanabenz—Paraesthesia—Capecitabine—prostate cancer	0.000122	0.000244	CcSEcCtD
Guanabenz—Decreased appetite—Docetaxel—prostate cancer	0.000122	0.000244	CcSEcCtD
Guanabenz—Oedema peripheral—Doxorubicin—prostate cancer	0.000121	0.000243	CcSEcCtD
Guanabenz—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000121	0.000242	CcSEcCtD
Guanabenz—Asthenia—Etoposide—prostate cancer	0.000121	0.000242	CcSEcCtD
Guanabenz—Connective tissue disorder—Doxorubicin—prostate cancer	0.000121	0.000242	CcSEcCtD
Guanabenz—Dyspnoea—Capecitabine—prostate cancer	0.000121	0.000242	CcSEcCtD
Guanabenz—Oedema—Prednisone—prostate cancer	0.000121	0.000242	CcSEcCtD
Guanabenz—Fatigue—Docetaxel—prostate cancer	0.000121	0.000242	CcSEcCtD
Guanabenz—Nausea—Mitoxantrone—prostate cancer	0.00012	0.000241	CcSEcCtD
Guanabenz—Immune system disorder—Epirubicin—prostate cancer	0.00012	0.000241	CcSEcCtD
Guanabenz—Infection—Prednisone—prostate cancer	0.00012	0.000241	CcSEcCtD
Guanabenz—Mediastinal disorder—Epirubicin—prostate cancer	0.00012	0.00024	CcSEcCtD
Guanabenz—Constipation—Docetaxel—prostate cancer	0.00012	0.00024	CcSEcCtD
Guanabenz—Pain—Docetaxel—prostate cancer	0.00012	0.00024	CcSEcCtD
Guanabenz—Dyspepsia—Capecitabine—prostate cancer	0.000119	0.000239	CcSEcCtD
Guanabenz—Chills—Epirubicin—prostate cancer	0.000119	0.000239	CcSEcCtD
Guanabenz—Pruritus—Etoposide—prostate cancer	0.000119	0.000239	CcSEcCtD
Guanabenz—Shock—Prednisone—prostate cancer	0.000119	0.000238	CcSEcCtD
Guanabenz—Nervous system disorder—Prednisone—prostate cancer	0.000119	0.000237	CcSEcCtD
Guanabenz—Tachycardia—Prednisone—prostate cancer	0.000118	0.000236	CcSEcCtD
Guanabenz—Decreased appetite—Capecitabine—prostate cancer	0.000118	0.000236	CcSEcCtD
Guanabenz—Skin disorder—Prednisone—prostate cancer	0.000117	0.000235	CcSEcCtD
Guanabenz—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000117	0.000235	CcSEcCtD
Guanabenz—Fatigue—Capecitabine—prostate cancer	0.000117	0.000234	CcSEcCtD
Guanabenz—Erythema multiforme—Doxorubicin—prostate cancer	0.000116	0.000233	CcSEcCtD
Guanabenz—Pain—Capecitabine—prostate cancer	0.000116	0.000232	CcSEcCtD
Guanabenz—Constipation—Capecitabine—prostate cancer	0.000116	0.000232	CcSEcCtD
Guanabenz—Erythema—Epirubicin—prostate cancer	0.000116	0.000232	CcSEcCtD
Guanabenz—Malnutrition—Epirubicin—prostate cancer	0.000116	0.000232	CcSEcCtD
Guanabenz—Feeling abnormal—Docetaxel—prostate cancer	0.000115	0.000231	CcSEcCtD
Guanabenz—Diarrhoea—Etoposide—prostate cancer	0.000115	0.000231	CcSEcCtD
Guanabenz—Anorexia—Prednisone—prostate cancer	0.000115	0.000231	CcSEcCtD
Guanabenz—Eye disorder—Doxorubicin—prostate cancer	0.000115	0.00023	CcSEcCtD
Guanabenz—Tinnitus—Doxorubicin—prostate cancer	0.000115	0.00023	CcSEcCtD
Guanabenz—Gastrointestinal pain—Docetaxel—prostate cancer	0.000115	0.00023	CcSEcCtD
Guanabenz—Flatulence—Epirubicin—prostate cancer	0.000114	0.000229	CcSEcCtD
Guanabenz—Tension—Epirubicin—prostate cancer	0.000114	0.000228	CcSEcCtD
Guanabenz—Nervousness—Epirubicin—prostate cancer	0.000112	0.000225	CcSEcCtD
Guanabenz—Back pain—Epirubicin—prostate cancer	0.000112	0.000224	CcSEcCtD
Guanabenz—Feeling abnormal—Capecitabine—prostate cancer	0.000112	0.000224	CcSEcCtD
Guanabenz—Dizziness—Etoposide—prostate cancer	0.000112	0.000223	CcSEcCtD
Guanabenz—Muscle spasms—Epirubicin—prostate cancer	0.000111	0.000223	CcSEcCtD
Guanabenz—Immune system disorder—Doxorubicin—prostate cancer	0.000111	0.000223	CcSEcCtD
Guanabenz—Gastrointestinal pain—Capecitabine—prostate cancer	0.000111	0.000222	CcSEcCtD
Guanabenz—Mediastinal disorder—Doxorubicin—prostate cancer	0.000111	0.000222	CcSEcCtD
Guanabenz—Body temperature increased—Docetaxel—prostate cancer	0.000111	0.000222	CcSEcCtD
Guanabenz—Abdominal pain—Docetaxel—prostate cancer	0.000111	0.000222	CcSEcCtD
Guanabenz—Chills—Doxorubicin—prostate cancer	0.00011	0.000221	CcSEcCtD
Guanabenz—Musculoskeletal discomfort—Prednisone—prostate cancer	0.00011	0.000221	CcSEcCtD
Guanabenz—Vision blurred—Epirubicin—prostate cancer	0.000109	0.000219	CcSEcCtD
Guanabenz—Paraesthesia—Prednisone—prostate cancer	0.000109	0.000217	CcSEcCtD
Guanabenz—Urticaria—Capecitabine—prostate cancer	0.000108	0.000216	CcSEcCtD
Guanabenz—Ill-defined disorder—Epirubicin—prostate cancer	0.000107	0.000215	CcSEcCtD
Guanabenz—Body temperature increased—Capecitabine—prostate cancer	0.000107	0.000215	CcSEcCtD
Guanabenz—Abdominal pain—Capecitabine—prostate cancer	0.000107	0.000215	CcSEcCtD
Guanabenz—Vomiting—Etoposide—prostate cancer	0.000107	0.000215	CcSEcCtD
Guanabenz—Erythema—Doxorubicin—prostate cancer	0.000107	0.000215	CcSEcCtD
Guanabenz—Malnutrition—Doxorubicin—prostate cancer	0.000107	0.000215	CcSEcCtD
Guanabenz—Anaemia—Epirubicin—prostate cancer	0.000107	0.000214	CcSEcCtD
Guanabenz—Agitation—Epirubicin—prostate cancer	0.000106	0.000213	CcSEcCtD
Guanabenz—Dyspepsia—Prednisone—prostate cancer	0.000106	0.000213	CcSEcCtD
Guanabenz—Rash—Etoposide—prostate cancer	0.000106	0.000213	CcSEcCtD
Guanabenz—Dermatitis—Etoposide—prostate cancer	0.000106	0.000213	CcSEcCtD
Guanabenz—Headache—Etoposide—prostate cancer	0.000106	0.000212	CcSEcCtD
Guanabenz—Flatulence—Doxorubicin—prostate cancer	0.000106	0.000212	CcSEcCtD
Guanabenz—Tension—Doxorubicin—prostate cancer	0.000105	0.000211	CcSEcCtD
Guanabenz—Decreased appetite—Prednisone—prostate cancer	0.000105	0.00021	CcSEcCtD
Guanabenz—Malaise—Epirubicin—prostate cancer	0.000104	0.000209	CcSEcCtD
Guanabenz—Fatigue—Prednisone—prostate cancer	0.000104	0.000209	CcSEcCtD
Guanabenz—Nervousness—Doxorubicin—prostate cancer	0.000104	0.000208	CcSEcCtD
Guanabenz—Syncope—Epirubicin—prostate cancer	0.000104	0.000208	CcSEcCtD
Guanabenz—Leukopenia—Epirubicin—prostate cancer	0.000104	0.000208	CcSEcCtD
Guanabenz—Back pain—Doxorubicin—prostate cancer	0.000104	0.000208	CcSEcCtD
Guanabenz—Constipation—Prednisone—prostate cancer	0.000103	0.000207	CcSEcCtD
Guanabenz—Hypersensitivity—Docetaxel—prostate cancer	0.000103	0.000207	CcSEcCtD
Guanabenz—Muscle spasms—Doxorubicin—prostate cancer	0.000103	0.000206	CcSEcCtD
Guanabenz—Loss of consciousness—Epirubicin—prostate cancer	0.000102	0.000204	CcSEcCtD
Guanabenz—Cough—Epirubicin—prostate cancer	0.000101	0.000202	CcSEcCtD
Guanabenz—Vision blurred—Doxorubicin—prostate cancer	0.000101	0.000202	CcSEcCtD
Guanabenz—Asthenia—Docetaxel—prostate cancer	0.000101	0.000201	CcSEcCtD
Guanabenz—Nausea—Etoposide—prostate cancer	0.0001	0.000201	CcSEcCtD
Guanabenz—Hypertension—Epirubicin—prostate cancer	0.0001	0.0002	CcSEcCtD
Guanabenz—Hypersensitivity—Capecitabine—prostate cancer	0.0001	0.0002	CcSEcCtD
Guanabenz—Feeling abnormal—Prednisone—prostate cancer	9.96e-05	0.000199	CcSEcCtD
Guanabenz—Ill-defined disorder—Doxorubicin—prostate cancer	9.94e-05	0.000199	CcSEcCtD
Guanabenz—Pruritus—Docetaxel—prostate cancer	9.92e-05	0.000199	CcSEcCtD
Guanabenz—Anaemia—Doxorubicin—prostate cancer	9.91e-05	0.000198	CcSEcCtD
Guanabenz—Gastrointestinal pain—Prednisone—prostate cancer	9.88e-05	0.000198	CcSEcCtD
Guanabenz—Chest pain—Epirubicin—prostate cancer	9.86e-05	0.000198	CcSEcCtD
Guanabenz—Myalgia—Epirubicin—prostate cancer	9.86e-05	0.000198	CcSEcCtD
Guanabenz—Arthralgia—Epirubicin—prostate cancer	9.86e-05	0.000198	CcSEcCtD
Guanabenz—Agitation—Doxorubicin—prostate cancer	9.85e-05	0.000197	CcSEcCtD
Guanabenz—Anxiety—Epirubicin—prostate cancer	9.83e-05	0.000197	CcSEcCtD
Guanabenz—Discomfort—Epirubicin—prostate cancer	9.74e-05	0.000195	CcSEcCtD
Guanabenz—Asthenia—Capecitabine—prostate cancer	9.74e-05	0.000195	CcSEcCtD
Guanabenz—Malaise—Doxorubicin—prostate cancer	9.66e-05	0.000194	CcSEcCtD
Guanabenz—Dry mouth—Epirubicin—prostate cancer	9.64e-05	0.000193	CcSEcCtD
Guanabenz—Syncope—Doxorubicin—prostate cancer	9.61e-05	0.000193	CcSEcCtD
Guanabenz—Urticaria—Prednisone—prostate cancer	9.6e-05	0.000192	CcSEcCtD
Guanabenz—Pruritus—Capecitabine—prostate cancer	9.6e-05	0.000192	CcSEcCtD
Guanabenz—Leukopenia—Doxorubicin—prostate cancer	9.59e-05	0.000192	CcSEcCtD
Guanabenz—Diarrhoea—Docetaxel—prostate cancer	9.59e-05	0.000192	CcSEcCtD
Guanabenz—Abdominal pain—Prednisone—prostate cancer	9.55e-05	0.000191	CcSEcCtD
Guanabenz—Body temperature increased—Prednisone—prostate cancer	9.55e-05	0.000191	CcSEcCtD
Guanabenz—Confusional state—Epirubicin—prostate cancer	9.53e-05	0.000191	CcSEcCtD
Guanabenz—Oedema—Epirubicin—prostate cancer	9.45e-05	0.000189	CcSEcCtD
Guanabenz—Loss of consciousness—Doxorubicin—prostate cancer	9.42e-05	0.000189	CcSEcCtD
Guanabenz—Infection—Epirubicin—prostate cancer	9.39e-05	0.000188	CcSEcCtD
Guanabenz—Cough—Doxorubicin—prostate cancer	9.35e-05	0.000187	CcSEcCtD
Guanabenz—Shock—Epirubicin—prostate cancer	9.3e-05	0.000186	CcSEcCtD
Guanabenz—Diarrhoea—Capecitabine—prostate cancer	9.28e-05	0.000186	CcSEcCtD
Guanabenz—Nervous system disorder—Epirubicin—prostate cancer	9.27e-05	0.000186	CcSEcCtD
Guanabenz—Dizziness—Docetaxel—prostate cancer	9.27e-05	0.000186	CcSEcCtD
Guanabenz—Thrombocytopenia—Epirubicin—prostate cancer	9.26e-05	0.000185	CcSEcCtD
Guanabenz—Hypertension—Doxorubicin—prostate cancer	9.25e-05	0.000185	CcSEcCtD
Guanabenz—Tachycardia—Epirubicin—prostate cancer	9.23e-05	0.000185	CcSEcCtD
Guanabenz—Skin disorder—Epirubicin—prostate cancer	9.18e-05	0.000184	CcSEcCtD
Guanabenz—Myalgia—Doxorubicin—prostate cancer	9.12e-05	0.000183	CcSEcCtD
Guanabenz—Chest pain—Doxorubicin—prostate cancer	9.12e-05	0.000183	CcSEcCtD
Guanabenz—Arthralgia—Doxorubicin—prostate cancer	9.12e-05	0.000183	CcSEcCtD
Guanabenz—Anxiety—Doxorubicin—prostate cancer	9.09e-05	0.000182	CcSEcCtD
Guanabenz—Discomfort—Doxorubicin—prostate cancer	9.01e-05	0.000181	CcSEcCtD
Guanabenz—Anorexia—Epirubicin—prostate cancer	9.01e-05	0.00018	CcSEcCtD
Guanabenz—Dizziness—Capecitabine—prostate cancer	8.97e-05	0.00018	CcSEcCtD
Guanabenz—Dry mouth—Doxorubicin—prostate cancer	8.92e-05	0.000179	CcSEcCtD
Guanabenz—Vomiting—Docetaxel—prostate cancer	8.91e-05	0.000178	CcSEcCtD
Guanabenz—Hypersensitivity—Prednisone—prostate cancer	8.9e-05	0.000178	CcSEcCtD
Guanabenz—Rash—Docetaxel—prostate cancer	8.84e-05	0.000177	CcSEcCtD
Guanabenz—Hypotension—Epirubicin—prostate cancer	8.83e-05	0.000177	CcSEcCtD
Guanabenz—Dermatitis—Docetaxel—prostate cancer	8.83e-05	0.000177	CcSEcCtD
Guanabenz—Confusional state—Doxorubicin—prostate cancer	8.82e-05	0.000177	CcSEcCtD
Guanabenz—Headache—Docetaxel—prostate cancer	8.78e-05	0.000176	CcSEcCtD
Guanabenz—Oedema—Doxorubicin—prostate cancer	8.75e-05	0.000175	CcSEcCtD
Guanabenz—Infection—Doxorubicin—prostate cancer	8.69e-05	0.000174	CcSEcCtD
Guanabenz—Asthenia—Prednisone—prostate cancer	8.67e-05	0.000174	CcSEcCtD
Guanabenz—Vomiting—Capecitabine—prostate cancer	8.63e-05	0.000173	CcSEcCtD
Guanabenz—Musculoskeletal discomfort—Epirubicin—prostate cancer	8.61e-05	0.000173	CcSEcCtD
Guanabenz—Shock—Doxorubicin—prostate cancer	8.61e-05	0.000172	CcSEcCtD
Guanabenz—Nervous system disorder—Doxorubicin—prostate cancer	8.58e-05	0.000172	CcSEcCtD
Guanabenz—Thrombocytopenia—Doxorubicin—prostate cancer	8.56e-05	0.000172	CcSEcCtD
Guanabenz—Rash—Capecitabine—prostate cancer	8.56e-05	0.000171	CcSEcCtD
Guanabenz—Pruritus—Prednisone—prostate cancer	8.55e-05	0.000171	CcSEcCtD
Guanabenz—Dermatitis—Capecitabine—prostate cancer	8.55e-05	0.000171	CcSEcCtD
Guanabenz—Tachycardia—Doxorubicin—prostate cancer	8.54e-05	0.000171	CcSEcCtD
Guanabenz—Headache—Capecitabine—prostate cancer	8.5e-05	0.00017	CcSEcCtD
Guanabenz—Skin disorder—Doxorubicin—prostate cancer	8.5e-05	0.00017	CcSEcCtD
Guanabenz—Paraesthesia—Epirubicin—prostate cancer	8.49e-05	0.00017	CcSEcCtD
Guanabenz—Dyspnoea—Epirubicin—prostate cancer	8.43e-05	0.000169	CcSEcCtD
Guanabenz—Anorexia—Doxorubicin—prostate cancer	8.34e-05	0.000167	CcSEcCtD
Guanabenz—Nausea—Docetaxel—prostate cancer	8.32e-05	0.000167	CcSEcCtD
Guanabenz—Dyspepsia—Epirubicin—prostate cancer	8.32e-05	0.000167	CcSEcCtD
Guanabenz—Diarrhoea—Prednisone—prostate cancer	8.27e-05	0.000166	CcSEcCtD
Guanabenz—Decreased appetite—Epirubicin—prostate cancer	8.22e-05	0.000165	CcSEcCtD
Guanabenz—Hypotension—Doxorubicin—prostate cancer	8.17e-05	0.000164	CcSEcCtD
Guanabenz—Gastrointestinal disorder—Epirubicin—prostate cancer	8.16e-05	0.000163	CcSEcCtD
Guanabenz—Fatigue—Epirubicin—prostate cancer	8.15e-05	0.000163	CcSEcCtD
Guanabenz—Pain—Epirubicin—prostate cancer	8.08e-05	0.000162	CcSEcCtD
Guanabenz—Constipation—Epirubicin—prostate cancer	8.08e-05	0.000162	CcSEcCtD
Guanabenz—Nausea—Capecitabine—prostate cancer	8.06e-05	0.000161	CcSEcCtD
Guanabenz—Dizziness—Prednisone—prostate cancer	7.99e-05	0.00016	CcSEcCtD
Guanabenz—Musculoskeletal discomfort—Doxorubicin—prostate cancer	7.97e-05	0.00016	CcSEcCtD
Guanabenz—Paraesthesia—Doxorubicin—prostate cancer	7.85e-05	0.000157	CcSEcCtD
Guanabenz—Dyspnoea—Doxorubicin—prostate cancer	7.8e-05	0.000156	CcSEcCtD
Guanabenz—Feeling abnormal—Epirubicin—prostate cancer	7.79e-05	0.000156	CcSEcCtD
Guanabenz—Gastrointestinal pain—Epirubicin—prostate cancer	7.73e-05	0.000155	CcSEcCtD
Guanabenz—Dyspepsia—Doxorubicin—prostate cancer	7.7e-05	0.000154	CcSEcCtD
Guanabenz—Vomiting—Prednisone—prostate cancer	7.68e-05	0.000154	CcSEcCtD
Guanabenz—Rash—Prednisone—prostate cancer	7.62e-05	0.000153	CcSEcCtD
Guanabenz—Dermatitis—Prednisone—prostate cancer	7.61e-05	0.000153	CcSEcCtD
Guanabenz—Decreased appetite—Doxorubicin—prostate cancer	7.6e-05	0.000152	CcSEcCtD
Guanabenz—Headache—Prednisone—prostate cancer	7.57e-05	0.000152	CcSEcCtD
Guanabenz—Gastrointestinal disorder—Doxorubicin—prostate cancer	7.55e-05	0.000151	CcSEcCtD
Guanabenz—Fatigue—Doxorubicin—prostate cancer	7.54e-05	0.000151	CcSEcCtD
Guanabenz—Urticaria—Epirubicin—prostate cancer	7.51e-05	0.00015	CcSEcCtD
Guanabenz—Pain—Doxorubicin—prostate cancer	7.48e-05	0.00015	CcSEcCtD
Guanabenz—Constipation—Doxorubicin—prostate cancer	7.48e-05	0.00015	CcSEcCtD
Guanabenz—Body temperature increased—Epirubicin—prostate cancer	7.47e-05	0.00015	CcSEcCtD
Guanabenz—Abdominal pain—Epirubicin—prostate cancer	7.47e-05	0.00015	CcSEcCtD
Guanabenz—Feeling abnormal—Doxorubicin—prostate cancer	7.21e-05	0.000144	CcSEcCtD
Guanabenz—Nausea—Prednisone—prostate cancer	7.18e-05	0.000144	CcSEcCtD
Guanabenz—Gastrointestinal pain—Doxorubicin—prostate cancer	7.15e-05	0.000143	CcSEcCtD
Guanabenz—Hypersensitivity—Epirubicin—prostate cancer	6.96e-05	0.000139	CcSEcCtD
Guanabenz—Urticaria—Doxorubicin—prostate cancer	6.95e-05	0.000139	CcSEcCtD
Guanabenz—Abdominal pain—Doxorubicin—prostate cancer	6.91e-05	0.000138	CcSEcCtD
Guanabenz—Body temperature increased—Doxorubicin—prostate cancer	6.91e-05	0.000138	CcSEcCtD
Guanabenz—Asthenia—Epirubicin—prostate cancer	6.78e-05	0.000136	CcSEcCtD
Guanabenz—Pruritus—Epirubicin—prostate cancer	6.69e-05	0.000134	CcSEcCtD
Guanabenz—Diarrhoea—Epirubicin—prostate cancer	6.47e-05	0.00013	CcSEcCtD
Guanabenz—Hypersensitivity—Doxorubicin—prostate cancer	6.44e-05	0.000129	CcSEcCtD
Guanabenz—Asthenia—Doxorubicin—prostate cancer	6.28e-05	0.000126	CcSEcCtD
Guanabenz—Dizziness—Epirubicin—prostate cancer	6.25e-05	0.000125	CcSEcCtD
Guanabenz—Pruritus—Doxorubicin—prostate cancer	6.19e-05	0.000124	CcSEcCtD
Guanabenz—Vomiting—Epirubicin—prostate cancer	6.01e-05	0.00012	CcSEcCtD
Guanabenz—Diarrhoea—Doxorubicin—prostate cancer	5.98e-05	0.00012	CcSEcCtD
Guanabenz—Rash—Epirubicin—prostate cancer	5.96e-05	0.000119	CcSEcCtD
Guanabenz—Dermatitis—Epirubicin—prostate cancer	5.95e-05	0.000119	CcSEcCtD
Guanabenz—Headache—Epirubicin—prostate cancer	5.92e-05	0.000119	CcSEcCtD
Guanabenz—Dizziness—Doxorubicin—prostate cancer	5.78e-05	0.000116	CcSEcCtD
Guanabenz—Nausea—Epirubicin—prostate cancer	5.61e-05	0.000112	CcSEcCtD
Guanabenz—Vomiting—Doxorubicin—prostate cancer	5.56e-05	0.000111	CcSEcCtD
Guanabenz—Rash—Doxorubicin—prostate cancer	5.51e-05	0.00011	CcSEcCtD
Guanabenz—Dermatitis—Doxorubicin—prostate cancer	5.51e-05	0.00011	CcSEcCtD
Guanabenz—Headache—Doxorubicin—prostate cancer	5.48e-05	0.00011	CcSEcCtD
Guanabenz—Nausea—Doxorubicin—prostate cancer	5.2e-05	0.000104	CcSEcCtD
Guanabenz—ADRA2A—Signaling Pathways—VAV3—prostate cancer	1.59e-05	9.9e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—AKT1—prostate cancer	1.59e-05	9.88e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	1.58e-05	9.88e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—PIK3CG—prostate cancer	1.57e-05	9.81e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—IL2—prostate cancer	1.57e-05	9.77e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—TGFBR2—prostate cancer	1.57e-05	9.76e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—TERT—prostate cancer	1.56e-05	9.73e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—LEP—prostate cancer	1.56e-05	9.73e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CAV1—prostate cancer	1.55e-05	9.64e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—ITPR1—prostate cancer	1.54e-05	9.61e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—HPGDS—prostate cancer	1.54e-05	9.59e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—KDR—prostate cancer	1.53e-05	9.53e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CYP2C19—prostate cancer	1.53e-05	9.53e-05	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—PIK3CB—prostate cancer	1.53e-05	9.52e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—MTHFR—prostate cancer	1.52e-05	9.48e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—HIF1A—prostate cancer	1.49e-05	9.31e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—PPARA—prostate cancer	1.49e-05	9.3e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—ACHE—prostate cancer	1.49e-05	9.3e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GSTT1—prostate cancer	1.49e-05	9.3e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—ESR1—prostate cancer	1.49e-05	9.29e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—INS—prostate cancer	1.49e-05	9.28e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—AKT1—prostate cancer	1.48e-05	9.23e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CYP2A6—prostate cancer	1.47e-05	9.19e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—IGF1R—prostate cancer	1.47e-05	9.19e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—PIK3CA—prostate cancer	1.47e-05	9.18e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	1.47e-05	9.16e-05	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—CXCL8—prostate cancer	1.47e-05	9.14e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—JAK2—prostate cancer	1.46e-05	9.1e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—CREBBP—prostate cancer	1.46e-05	9.09e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—LEP—prostate cancer	1.46e-05	9.09e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—BAD—prostate cancer	1.45e-05	9.07e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CAV1—prostate cancer	1.44e-05	9e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—AKR1C3—prostate cancer	1.43e-05	8.94e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—KDR—prostate cancer	1.43e-05	8.9e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PRKACB—prostate cancer	1.43e-05	8.89e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—TP53—prostate cancer	1.42e-05	8.88e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—LPL—prostate cancer	1.41e-05	8.81e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CYP17A1—prostate cancer	1.41e-05	8.8e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—APC—prostate cancer	1.41e-05	8.78e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—PIK3CG—prostate cancer	1.41e-05	8.78e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—CAV1—prostate cancer	1.4e-05	8.75e-05	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—IL2—prostate cancer	1.4e-05	8.74e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PDGFRB—prostate cancer	1.4e-05	8.73e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	1.39e-05	8.68e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—EGF—prostate cancer	1.39e-05	8.68e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—IRS1—prostate cancer	1.39e-05	8.68e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—ESR1—prostate cancer	1.39e-05	8.68e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—PIK3CB—prostate cancer	1.39e-05	8.64e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—PIK3CD—prostate cancer	1.38e-05	8.62e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—ITGB3—prostate cancer	1.36e-05	8.5e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—BAD—prostate cancer	1.36e-05	8.47e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—GSK3B—prostate cancer	1.35e-05	8.43e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—NCOA2—prostate cancer	1.35e-05	8.39e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—INS—prostate cancer	1.33e-05	8.31e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—CXCL8—prostate cancer	1.33e-05	8.3e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—ERBB3—prostate cancer	1.32e-05	8.25e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—FGFR2—prostate cancer	1.32e-05	8.24e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—APC—prostate cancer	1.32e-05	8.2e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—PIK3CG—prostate cancer	1.32e-05	8.2e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—NOS3—prostate cancer	1.31e-05	8.14e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CREBBP—prostate cancer	1.31e-05	8.14e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—EGF—prostate cancer	1.3e-05	8.11e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—IRS1—prostate cancer	1.3e-05	8.11e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—IGF1—prostate cancer	1.29e-05	8.04e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—SLC5A5—prostate cancer	1.28e-05	8e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—EGFR—prostate cancer	1.28e-05	8e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—PIK3CG—prostate cancer	1.28e-05	7.97e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—IL2—prostate cancer	1.27e-05	7.94e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—TERT—prostate cancer	1.27e-05	7.91e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—GSK3B—prostate cancer	1.26e-05	7.87e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CYP2E1—prostate cancer	1.25e-05	7.82e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—MAP2K1—prostate cancer	1.25e-05	7.77e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—INS—prostate cancer	1.25e-05	7.76e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—NQO1—prostate cancer	1.24e-05	7.73e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—PIK3CD—prostate cancer	1.24e-05	7.72e-05	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR downstream signaling—PIK3CA—prostate cancer	1.23e-05	7.65e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—SERPINE1—prostate cancer	1.23e-05	7.63e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—TH—prostate cancer	1.22e-05	7.62e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CREBBP—prostate cancer	1.22e-05	7.6e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.21e-05	7.57e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—HIF1A—prostate cancer	1.21e-05	7.56e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—KRAS—prostate cancer	1.21e-05	7.56e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—INS—prostate cancer	1.21e-05	7.54e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CYP3A4—prostate cancer	1.21e-05	7.54e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—PIK3CB—prostate cancer	1.21e-05	7.52e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—IGF1—prostate cancer	1.21e-05	7.51e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—AKT1—prostate cancer	1.2e-05	7.5e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.2e-05	7.5e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—EGFR—prostate cancer	1.2e-05	7.47e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—PTGS2—prostate cancer	1.19e-05	7.45e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CYP1B1—prostate cancer	1.19e-05	7.41e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—FGF2—prostate cancer	1.19e-05	7.39e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—CREBBP—prostate cancer	1.19e-05	7.39e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—LEP—prostate cancer	1.18e-05	7.38e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CAV1—prostate cancer	1.17e-05	7.31e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—NOS3—prostate cancer	1.17e-05	7.29e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—MAP2K1—prostate cancer	1.16e-05	7.26e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—KDR—prostate cancer	1.16e-05	7.23e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—PIK3CD—prostate cancer	1.16e-05	7.21e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GGT1—prostate cancer	1.15e-05	7.18e-05	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR downstream signaling—PIK3CA—prostate cancer	1.15e-05	7.14e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—SERPINE1—prostate cancer	1.14e-05	7.13e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—JAK2—prostate cancer	1.14e-05	7.08e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—NCOA1—prostate cancer	1.13e-05	7.07e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—KRAS—prostate cancer	1.13e-05	7.06e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—ESR1—prostate cancer	1.13e-05	7.05e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—PIK3CD—prostate cancer	1.12e-05	7e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CYP19A1—prostate cancer	1.12e-05	6.97e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—PIK3CA—prostate cancer	1.11e-05	6.94e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—MDM2—prostate cancer	1.11e-05	6.91e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—FGF2—prostate cancer	1.11e-05	6.9e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—BAD—prostate cancer	1.1e-05	6.88e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—ERBB2—prostate cancer	1.09e-05	6.82e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—NOS3—prostate cancer	1.09e-05	6.81e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—PIK3CB—prostate cancer	1.08e-05	6.73e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—RXRA—prostate cancer	1.08e-05	6.72e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—APC—prostate cancer	1.07e-05	6.66e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PIK3CG—prostate cancer	1.07e-05	6.66e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—JAK2—prostate cancer	1.06e-05	6.62e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—NOS3—prostate cancer	1.06e-05	6.61e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—EGF—prostate cancer	1.06e-05	6.58e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—IRS1—prostate cancer	1.06e-05	6.58e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.05e-05	6.54e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—PTEN—prostate cancer	1.04e-05	6.49e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—PIK3CA—prostate cancer	1.04e-05	6.49e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—COMT—prostate cancer	1.04e-05	6.48e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CXCL8—prostate cancer	1.04e-05	6.47e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—MDM2—prostate cancer	1.04e-05	6.46e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GSTP1—prostate cancer	1.03e-05	6.45e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—GSK3B—prostate cancer	1.03e-05	6.39e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—ERBB2—prostate cancer	1.02e-05	6.37e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—ITPR1—prostate cancer	1.02e-05	6.34e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CDKN1B—prostate cancer	1.01e-05	6.31e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—INS—prostate cancer	1.01e-05	6.31e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—PIK3CB—prostate cancer	1.01e-05	6.28e-05	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR downstream signaling—AKT1—prostate cancer	1e-05	6.25e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1e-05	6.24e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—EP300—prostate cancer	9.94e-06	6.19e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CASP3—prostate cancer	9.93e-06	6.19e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—IL2—prostate cancer	9.91e-06	6.18e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CREBBP—prostate cancer	9.91e-06	6.18e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—IL6—prostate cancer	9.87e-06	6.15e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—PIK3CB—prostate cancer	9.8e-06	6.1e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—IGF1—prostate cancer	9.79e-06	6.1e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—EGFR—prostate cancer	9.74e-06	6.07e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—PTGS2—prostate cancer	9.71e-06	6.05e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CXCL8—prostate cancer	9.69e-06	6.04e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CCND1—prostate cancer	9.67e-06	6.02e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—TYMS—prostate cancer	9.62e-06	5.99e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CTNNB1—prostate cancer	9.57e-06	5.96e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GSTM1—prostate cancer	9.5e-06	5.92e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CDKN1B—prostate cancer	9.46e-06	5.9e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—MAP2K1—prostate cancer	9.46e-06	5.9e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PIK3CD—prostate cancer	9.4e-06	5.86e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—MMP9—prostate cancer	9.38e-06	5.85e-05	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR downstream signaling—AKT1—prostate cancer	9.36e-06	5.83e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CDKN1A—prostate cancer	9.35e-06	5.83e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—LPL—prostate cancer	9.33e-06	5.81e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—PTEN—prostate cancer	9.33e-06	5.81e-05	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—PIK3CA—prostate cancer	9.31e-06	5.8e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—SERPINE1—prostate cancer	9.29e-06	5.79e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CASP3—prostate cancer	9.28e-06	5.78e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—IL2—prostate cancer	9.26e-06	5.77e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—IL6—prostate cancer	9.22e-06	5.74e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—KRAS—prostate cancer	9.2e-06	5.73e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—AKT1—prostate cancer	9.1e-06	5.67e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CCND1—prostate cancer	9.03e-06	5.63e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CYP1A1—prostate cancer	9.01e-06	5.61e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—FGF2—prostate cancer	9e-06	5.61e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CTNNB1—prostate cancer	8.94e-06	5.57e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—ERCC2—prostate cancer	8.94e-06	5.57e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—EP300—prostate cancer	8.9e-06	5.54e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—NOS3—prostate cancer	8.87e-06	5.53e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—MMP9—prostate cancer	8.77e-06	5.46e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CDKN1A—prostate cancer	8.73e-06	5.44e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—PTEN—prostate cancer	8.71e-06	5.43e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—SRC—prostate cancer	8.65e-06	5.39e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—JAK2—prostate cancer	8.62e-06	5.37e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—AKT1—prostate cancer	8.5e-06	5.3e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—PTEN—prostate cancer	8.46e-06	5.28e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—PIK3CA—prostate cancer	8.45e-06	5.27e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—VEGFA—prostate cancer	8.43e-06	5.25e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—MDM2—prostate cancer	8.42e-06	5.25e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—MTHFR—prostate cancer	8.4e-06	5.23e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—STAT3—prostate cancer	8.34e-06	5.2e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—EP300—prostate cancer	8.31e-06	5.18e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—ERBB2—prostate cancer	8.3e-06	5.17e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PPARA—prostate cancer	8.24e-06	5.14e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PIK3CB—prostate cancer	8.19e-06	5.1e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—SRC—prostate cancer	8.08e-06	5.04e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—EP300—prostate cancer	8.07e-06	5.03e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CXCL8—prostate cancer	7.87e-06	4.91e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—VEGFA—prostate cancer	7.87e-06	4.9e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—STAT3—prostate cancer	7.79e-06	4.86e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—MYC—prostate cancer	7.75e-06	4.83e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CAV1—prostate cancer	7.75e-06	4.83e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—TGFB1—prostate cancer	7.73e-06	4.82e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CDKN1B—prostate cancer	7.69e-06	4.79e-05	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—AKT1—prostate cancer	7.6e-06	4.74e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—EGFR—prostate cancer	7.58e-06	4.73e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CASP3—prostate cancer	7.53e-06	4.69e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—IL2—prostate cancer	7.52e-06	4.69e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—IL6—prostate cancer	7.48e-06	4.66e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	7.4e-06	4.61e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—PIK3CA—prostate cancer	7.35e-06	4.58e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CCND1—prostate cancer	7.33e-06	4.57e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CTNNB1—prostate cancer	7.26e-06	4.53e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—MYC—prostate cancer	7.24e-06	4.51e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—TGFB1—prostate cancer	7.22e-06	4.5e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—KRAS—prostate cancer	7.16e-06	4.46e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—MMP9—prostate cancer	7.12e-06	4.44e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CDKN1A—prostate cancer	7.09e-06	4.42e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—EGFR—prostate cancer	7.08e-06	4.41e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PTEN—prostate cancer	7.08e-06	4.41e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PIK3CG—prostate cancer	7.06e-06	4.4e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—AKT1—prostate cancer	6.91e-06	4.3e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—EP300—prostate cancer	6.75e-06	4.21e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—KRAS—prostate cancer	6.69e-06	4.17e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—INS—prostate cancer	6.68e-06	4.16e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—PIK3CA—prostate cancer	6.58e-06	4.1e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—SRC—prostate cancer	6.56e-06	4.09e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CREBBP—prostate cancer	6.54e-06	4.08e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—VEGFA—prostate cancer	6.39e-06	3.98e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—TP53—prostate cancer	6.37e-06	3.97e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—STAT3—prostate cancer	6.33e-06	3.94e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PIK3CD—prostate cancer	6.2e-06	3.87e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—PIK3CA—prostate cancer	6.15e-06	3.83e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—AKT1—prostate cancer	6.01e-06	3.74e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—PIK3CA—prostate cancer	5.97e-06	3.72e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—TP53—prostate cancer	5.95e-06	3.71e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—MYC—prostate cancer	5.88e-06	3.67e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—TGFB1—prostate cancer	5.87e-06	3.66e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—NOS3—prostate cancer	5.86e-06	3.65e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—IL6—prostate cancer	5.83e-06	3.63e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—EGFR—prostate cancer	5.75e-06	3.59e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—IL6—prostate cancer	5.44e-06	3.39e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—KRAS—prostate cancer	5.44e-06	3.39e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PIK3CB—prostate cancer	5.41e-06	3.37e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—AKT1—prostate cancer	5.38e-06	3.35e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PTGS2—prostate cancer	5.36e-06	3.34e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—AKT1—prostate cancer	5.02e-06	3.13e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PIK3CA—prostate cancer	4.99e-06	3.11e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—AKT1—prostate cancer	4.88e-06	3.04e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—TP53—prostate cancer	4.83e-06	3.01e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PTEN—prostate cancer	4.67e-06	2.91e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—EP300—prostate cancer	4.46e-06	2.78e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—IL6—prostate cancer	4.42e-06	2.76e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—AKT1—prostate cancer	4.08e-06	2.54e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PIK3CA—prostate cancer	3.3e-06	2.05e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—AKT1—prostate cancer	2.69e-06	1.68e-05	CbGpPWpGaD
